慢性好酸球性白血病の世界市場（2022年～2029年）

当レポートでは、世界の慢性好酸球性白血病市場について調査分析し、市場力学、業界分析、市場分析、競合情勢など、体系的な情報を提供しています。

目次

第1章 世界の慢性好酸球性白血病市場の調査手法と範囲

• 調査手法
• 調査の目的と調査範囲

第2章 世界の慢性好酸球性白血病市場－市場の定義と概要

第3章 世界の慢性好酸球性白血病市場－エグゼクティブサマリー

• 市場の内訳：薬剤タイプ別
• 市場の内訳：投与経路別
• 市場の内訳：流通チャネル別
• 市場の内訳：地域別

第4章 世界の慢性好酸球性白血病市場－市場力学

• 市場に影響を与える要因
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析

第5章 世界の慢性好酸球性白血病市場－業界分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 償還分析

第6章 世界の慢性好酸球性白血病市場－COVID-19分析

• 市場のCOVID-19分析
  • COVID-19以前の市場シナリオ
  • 現在のCOVID-19の市場シナリオ
  • COVID-19以後の市場シナリオ/将来の市場シナリオ
• COVID-19における価格の力学
• 需要と供給のスペクトル
• パンデミック時の市場に関連する政府のイニシアチブ
• メーカーの戦略的イニシアチブ
• 結論

第7章 世界の慢性好酸球性白血病市場：薬剤タイプ別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）：薬剤タイプ別
  • 市場魅力指数：薬剤タイプ別
• Gleevec*
  • イントロダクション
  • 市場規模分析、100万米ドル（2018年～2028年）、および前年比成長分析（％）（2020年～2028年）
• Imatinib
• Interferon alfa
• Hydroyurea
• Cytoxan
• Procytox
• Oncovin
• その他

第8章 世界の慢性好酸球性白血病市場：投与経路別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）：投与経路別
  • 市場魅力指数：投与経路別
• 経口*
  • イントロダクション
  • 市場規模分析、100万米ドル（2018年～2028年）、および前年比成長分析（％）（2020年～2028年）
• 注射

第9章 世界の慢性好酸球性白血病市場：流通チャネル別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）：流通チャネル別
  • 市場魅力指数：流通チャネル別
• 病院薬局*
  • イントロダクション
  • 市場規模分析、100万米ドル（2018年～2028年）、および前年比成長分析（％）（2020年～2028年）
• オンライン薬局
• 小売薬局
• その他

第10章 世界の慢性好酸球性白血病市場：地域別

• イントロダクション
  • 市場規模分析、100万米ドル（2018年～2028年）、および前年比成長分析（％）（2020年～2028年）：地域別
  • 市場魅力指数：地域別
• 北米
• 欧州
• 南米
• アジア太平洋
• 中東とアフリカ

第11章 世界の慢性好酸球性白血病市場－競合情勢

• 主な開発と戦略
• 企業シェア分析
• 製品のベンチマーク
• 注目すべき主要企業

第12章 世界の慢性好酸球性白血病市場－企業プロファイル概要

• Novartis AG*
  • 企業概要
  • 製品ポートフォリオおよび説明
  • 主要ハイライト
  • 財務概要
• GlaxoSmithKline plc
• Bristol-Myers Squibb Company
• F.Hoffmann-La Roche Ltd
• Eli Lilly and Company
• Hikma Pharmaceuticals plc
• Cipla Inc
• Amneal Pharmaceuticals,LLC
• Jiangsu Hengrui Medicine Co.Ltd
• EndoInternational Inc

第13章 世界の慢性好酸球性白血病市場－DataM

• 付録
• 当社・サービスについて
• お問い合わせ

Market Overview

The global chronic eosinophilic leukemia market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Chronic eosinophilic leukemia is a subtype of clonal eosinophilia caused by a new genetic mutation or change in blood cells. It is also known as a hypereosinophilic syndrome (HES). This condition is known as a myeloproliferative neoplasm (MPN).

Market Dynamics

The chronic eosinophilic leukemia market is expected to grow due to increased awareness of the condition, increased investment by major players globally, increased government initiatives, and a robust product pipeline. Furthermore, the rising prevalence of various health conditions that result in chronic eosinophilic leukemia, such as cancer,autoimmune disorders, endocrine disorders, and adrenal disorders, is expected to drive the chronic eosinophilic leukemia market. Increased healthcare spending and increased cancer awareness by government and private organizations are expected to drive market growth. Furthermore, during the forecast period, R&D activities related to chronic eosinophilic leukemia are expected to present new opportunities.

Increase in prevalance of blood borne diseases in the market will drive the market growth

The market for chronic eosinophilic leukemia components is being pushed by an increase in cancer cases,autoimmune disorders,endocrine disorders and adrenal disorders. According to the National Cancer Institute, in June 2017, it was estimated that there would be approximately 62,130 new cases and 24,500 deaths due to leukemia in the United States.

The Autoimmune Related Diseases Association estimates that up to 50 million Americans suffer from an autoimmune disease at the cost of $86 billion per year. According to the United States Department of HHS, these diseases are the fourth leading cause of disability amid women in the United States and the eighth leading cause of death amid women aged 15 to 64.

Adrenal disorders affect approximately 100 to 140 people out of every million in developed countries.Secondary adrenal insufficiency is more prevalent, affecting 150 to 280 people per million people.(Source-National Institutes of Health).

Evidence suggests that the global burden of endocrine disorders is increasing due to an aging population, obesity, poor lifestyle and dietary habits. Endocrine disorders affect about 5% of the population in the United States.The exact prevalence of endocrine disorders in Indians is unknown. Thyroid disorders and diabetes are the most common endocrine disorders in India.Diabetes affects 11.8 percent of the Indian population, accounting for 72.96 million adult cases. In India's adult population, the overall prevalence of hypothyroidism is around 10.9 percent.

Furthermore, the burden of blood-borne diseases has increased in recent years, along with the rising prevalence of geriatric population, raising public awareness about treatment available, and several government initiatives related to chronic eosinophilic leukemia , all of which are driving the overall market.This contributes to the growth of the global chronic eosinophilic leukemia market.

High cost of treatment is likely to hamper the market growth

The lack of awareness of hypereosinophilic syndrome in emerging regions and the high cost of treatment and poor health care infrastructure in developing nations is expected to limit the hypereosinophilic syndrome market over the projection period. High cost of treatment is the major drawback which is likely to hamper the market . Majority of under developed and developing countries are facing this problem due to less share from the government sector. There is a lot of pressure to cut costs and show value. Political uncertainty and persistent economic stress in many countries are jeopardizing public health care funding. In less developed countries, a lack of cost-effective drugs has influenced population health and resulted in a low average life expectancy.

COVID-19 Impact Analysis

Over the projection period, the increased prevalence of COVID-19 is expected to impact chronic eosinophilic leukemia market growth. The majority of pharmaceutical businesses have suffered considerable losses due to the coronavirus outbreak, which has hampered the chronic eosinophilic leukemia market. The COVID-19 pandemic has had a remarkable influence on the global economy; this has significantly impacted production processes and demand across multiple verticals and disrupted the supply chain. During the initial phase of the COVID, many businesses ceased manufacturing and supply operations. However, the current COVID-19 situation is expected to return to normalcy as medical professionals and health authorities in the countries take the necessary steps to combat the virus.

Segment Analysis

The injectables segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Over the forecast period, the injectables segment is expected to increase . The rising number of autoimmune disorders, the rising number of chronic eosinophilic leukemia cases, and the rising frequency of chronic disease-induced diabetes and cancer contribute to the segment's rise. For example, According to WHO, Cancer is the largest cause of death in the world, with approximately 10 million fatalities expected by 2020.

Furthermore, benralizumab as the first line of eosinophilia treatment.Major key players Like GlaxoSmithKline,Bristol-Myers Squibb are also doing R&D in this segment so these factors play a key role in development of this segment.

Geographical Analysis

North America region holds the largest market share of global chronic eosinophilic leukemia market

Due to rising cancer occurrences and rising healthcare concerns, North America is likely to hold a significant market position in the global chronic eosinophilic leukemia market. According to the National Cancer Institute, an estimated 1.7 million new instances of cancer were identified in 2018 in which these medications were used, boosting the imatinib drug market. Furthermore, the chronic eosinophilic leukemia market in North America is expected to benefit from increased R&D spending in healthcare (oncology). Furthermore, rising healthcare spending and the well-established healthcare infrastructure contribute to the overall regional market's growth. Furthermore, the presence of many key players in North America is a major factor driving market growth.

However, Asia-Pacific is assessed to grow the fastest during the forecast period, owing to increased healthcare spending and increased health-care spending, and technological advancements which contribute to the growth of the Asia-Pacific chronic eosinophilic leukemia market.

Competitive Landscape

The chronic eosinophilic leukemia market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Novartis,GlaxoSmithKline plc,Bristol-Myers Squibb Company,F.Hoffmann-La Roche Ltd,Eli Lilly and Company, Hikma Pharmaceuticals plc, Cipla Inc, Amneal Pharmaceuticals, LLC, Jiangsu Hengrui Medicine Co.Ltd, Bristol-Myers Squibb Company,Endo International Inc.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the chronic eosinophilic leukemia market globally. For instance May 2020, The US Food and Drug Administration (FDA) has given GlaxoSmithKline plc's (GSK) application for approval of Nucala (mepolizumab) in the treatment of individuals with Hypereosinophilic Syndrome (HES) in the US a priority review.

Novartis AG

Overview: Novartis India Ltd is an Indian based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company focuses on three divisions namely Pharmaceuticals , eyecare and generic medicines.

Product Portfolio:

Imatinib: Imatinib, also known as Gleevec and Glivec (both marketed globally by Novartis), is an oral chemotherapy medication used to treat cancer. It is used to treat Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome.It is taken orally.

Why Purchase the Report?

Visualize the composition of the global chronic eosinophilic leukemia market segmentation by drug type, route of administration, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in global chronic eosinophilic leukemia market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global chronic eosinophilic leukemia market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global chronic eosinophilic leukemia market report would provide an access to an approximately 40+ market data table, 45+ figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Chronic Eosinophilic Leukemia Market- By Drug Type

Gleevec

Imatinib

Interferon alfa

Hydroyurea

Cytoxan

Procytox

Others

Global Chronic Eosinophilic Leukemia Market- By Route of Administration

Oral

Injectable

Global Chronic Eosinophilic Leukemia Market- By Distribution Channel

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Others

Global Chronic Eosinophilic Leukemia Market- By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America

Table of Contents

1. Global Chronic Eosinophilic Leukemia Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Global Chronic Eosinophilic Leukemia Market- Market Definition and Overview

3. Global Chronic Eosinophilic Leukemia Market- Executive Summary

• 3.1. Market Snippet by Drug Type
• 3.2. Market snippet by Route of Administration
• 3.3. Market snippet by Distribution Channel
• 3.4. Market Snippet by Region

4. Global Chronic Eosinophilic Leukemia Market- Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in prevalence of cancer cases, autoimmune disorders, endocrine disorders across the globe.
    • 4.1.1.2. Technological advancement
  • 4.1.2. Restraints:
    • 4.1.2.1. Lack of awareness about chronic eosinophilic leukemia in developing countries.
    • 4.1.2.2. Poor healthcare infrastructure
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Global Chronic Eosinophilic Leukemia Market- Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis

6. Global Chronic Eosinophilic Leukemia Market- COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Global Chronic Eosinophilic Leukemia Market- By Drug Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
  • 7.1.2. Market Attractiveness Index, By Drug Type Segment
• 7.2. Gleevec*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
• 7.3. Imatinib
• 7.4. Interferon alfa
• 7.5. Hydroyurea
• 7.6. Cytoxan
• 7.7. Procytox
• 7.8. Oncovin
• 7.9. Others

8. Global Chronic Eosinophilic Leukemia Market- By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
• 8.3. Injectable

9. Global Chronic Eosinophilic Leukemia Market- By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
• 9.2. Hospital Pharmacies *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
• 9.3. Online Pharmacies
• 9.4. Retail Pharmacies
• 9.5. Others

10. Global Chronic Eosinophilic Leukemia Market- By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.5. Market Size Analysis ,and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Distribution Channel
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Route of Administration
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Chronic Eosinophilic Leukemia Market- Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking
• 11.4. Key Companies to Watch

12. Global Chronic Eosinophilic Leukemia Market- Company Profiles

• 12.1. Novartis AG*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. GlaxoSmithKline plc
• 12.3. Bristol-Myers Squibb Company
• 12.4. F.Hoffmann-La Roche Ltd
• 12.5. Eli Lilly and Company
• 12.6. Hikma Pharmaceuticals plc
• 12.7. Cipla Inc
• 12.8. Amneal Pharmaceuticals,LLC
• 12.9. Jiangsu Hengrui Medicine Co.Ltd
• 12.10. EndoInternational Inc

LIST NOT EXHAUSTIVE

13. Global Chronic Eosinophilic Leukemia Market- DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us